Biocon has received the green light from the Food and Drug Administration, for its complex formulation liraglutide injection, 18 mg/3 ml (6 mg/ml) single-patient-use prefilled pen ...

The medication is indicated as an adjunct to a reduced–calorie diet and increased physical activity for chronic weight management.

Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Obesity and weight-related health conditions have steadily risen over the past few decades, making weight management a ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication. It helps with sustained weight loss for adults with obesity, adults with overweight who are experiencing weight-related health issues ...

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) ...

In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight loss drug, reveals significant declines in bone ...

(RTTNews) - Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Thursday said that the U.S. Food and Drug Administration (FDA) has approved a generic version of ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...